BioTech Immuncore has revealed a £55 million funding round and has filed for a stock market flotation in the US.  The Oxford-based company delivers biological therapies that have the potential to transform the lives of people with serious diseases including cancer.  The Series C funding follows positive Phase 3 trial interim analysis data for its lead programme tebentafusp, which aims to help patients with … Continue reading Immunocore files for US IPO, secures £55m funding